As of November 6, 2026, Benitec Biopharma Inc. is a publicly traded company (Nasdaq: BNTC). The largest holder reporting an active stake on Schedule 13D is Suvretta Capital Management, LLC, at 44.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Franklin Resources, Inc. (10.6%), Janus Henderson (9.99%), RA Capital (5.5%) (Schedule 13D/A, November 10, 2025).
Is this your company?
About to sign with, pay or invest in Benitec Biopharma Inc.? See the free Snapshot first.
Free to see. No signup.
Is Benitec Biopharma Inc. a real, registered company?
- Benitec Biopharma Inc. files with the SEC under CIK 1808898 (its SEC filings).
- Its shares are listed under the ticker BNTC on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Hayward, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Benitec Biopharma Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is David Friedman, Director (Form 8-K filed 2026-05-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Franklin Resources, Inc. (filed 2026-01-29).
Who are Benitec Biopharma Inc.'s owners and officers?
Benitec Biopharma Inc.: incorporated in Delaware; business address in Hayward, California; industry Pharmaceutical Preparations (Form D, 2026-05-29).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-04-25)
- : Executive Officer, Director (Form D, 2024-04-25)
- : Director (Form D, 2024-04-25)
- : Director (Form D, 2024-04-25)
- : Director (Form D, 2024-04-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-01-29 | Franklin Resources, Inc. | 10.6% |
| Schedule 13G/A, 2025-12-08 | Janus Henderson Group PLC | 9.99% |
| Schedule 13G, 2025-12-03 | Ra Capital Management, L.P. | 5.5% |
| Schedule 13D/A, 2025-11-10 | Suvretta Capital Management, LLC | 44.1% |
| Schedule 13G/A, 2025-11-04 | Franklin Resources, Inc. | 14.9% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 11.3% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 11.3% |
Questions about who owns Benitec Biopharma Inc.
Who owns Benitec Biopharma Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Benitec Biopharma Inc.: Suvretta Capital Management, LLC (44.1%, Schedule 13D/A, filed 2025-11-10), Franklin Resources, Inc. (10.6%, Schedule 13G/A, filed 2026-01-29), Janus Henderson Group PLC (9.99%, Schedule 13G/A, filed 2025-12-08) and Ra Capital Management, L.P. (5.5%, Schedule 13G, filed 2025-12-03).
Who are the largest shareholders of Benitec Biopharma Inc.?
By the share each holder's latest filing reports, the largest holders of Benitec Biopharma Inc. on this page are Suvretta Capital Management, LLC (44.1%), Franklin Resources, Inc. (10.6%) and Janus Henderson Group PLC (9.99%).
When did Suvretta Capital Management, LLC buy into Benitec Biopharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Suvretta Capital Management, LLC on this page is the Schedule 13D/A, filed 2025-11-10, reporting 44.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Benitec Biopharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Benitec Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Benitec Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-29 | David Friedman | Director | appointed |
Which insiders own Benitec Biopharma Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 1,848,156 shares (5.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Averill Master Fund, Ltd., a director and 10% owner: 1,848,156 shares (5.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Suvretta Capital Management, LLC, a director and 10% owner: 1,848,156 shares (5.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Averill Madison Master Fund, Ltd., a 10% owner: 1,848,156 shares (5.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- , a director: 52,097 shares (0.15% of shares outstanding) (Form 4, 2026-06-30).
Shares outstanding: 34,882,726 as of 2026-09-04, from the company's latest SEC cover page.
How much has Benitec Biopharma Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-04-25 | $40M | $40M |
Keep reading
More on Benitec Biopharma Inc. and the records around it.
Benitec Biopharma Inc. elsewhere on the record
- Leadership changes May 2026
- 5%+ stake filings Jan 2026
Companies that share a holder
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Franklin Resources, Inc. also filed stake reports on 41 other companies: Adicet Bio, Inc. (Oct 2026), ALBEMARLE CORPORATION (Oct 2026), Andersen Group Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/benitec-biopharma